Next Generation Flow Technology for Minimal Residual Disease Detection in Multiple Myeloma Clinical Trials

Join a 59-minute webinar led by Dr. Bruno Paiva exploring the advanced capabilities of Next Generation Flow™ Technology in detecting minimal residual disease (MRD) in Multiple Myeloma. Discover how this highly sensitive and standardized technology revolutionizes MRD detection while learning about the International Myeloma Working Group (IMWG) criteria for MRD negativity. Gain valuable insights into the interpretation of clinical trial results, understand the technology's high concordance with other detection techniques, and explore the FDA/ODAC hearing findings regarding MRD negative CR endpoint. Master the practical aspects of result reproducibility between clinical trials and routine practice, bridging the crucial gap between research findings and real-world applications in patient care. Learn from a leading expert about implementing standardized procedures, evaluating detection methods, and applying this knowledge to enhance clinical research and treatment outcomes.